1st Clinical Trial of Potential Ulcerative Colitis Treatment, Oral Brilacidin, in Planning Phase – IBD News Today

Innovation Pharmaceuticals is planning a first clinical trial of an oral formulation ofBrilacidinas a treatment forulcerative colitis (UC), one of the most common types of inflammatory bowel disease (IBD).Brilacidin is a synthetic small molecule that belongs to a new class of compounds known as defensin-mimetics. It is structurally similarity to proteins naturally produced in the body that fend off bacteria and other microbes.Preclinical and clinical data have demonstrated that this compound holds strong immunomodulatory, anti-inflammatory, and anti-infective properties."With pharmaceutical industry interest in defensin-based therapies intensifying ... the planned upcoming UC program trial couldnt be happening at a better time an opportunity to further develop Brilacidins platform potential," Leo Ehrlich, CEO of Innovation, said in a press release."Defensins function in a broad immunomodulatory capacity, exhibiting beneficial characteristics, both anti-inflammatory and anti-infective. Defensin-based therapies thus have the unique potential to treat a wide array of diseases," Ehrlich added. "Brilacidin is the only defensin-based drug candidate in later-stage clinical testing now anchored by successful results in acute bacterial skin and skin structure infection, oral mucositis,

The rest is here:
1st Clinical Trial of Potential Ulcerative Colitis Treatment, Oral Brilacidin, in Planning Phase - IBD News Today